Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure. A one-month study.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Ophthalmology (Rochester, Minn.)

• Publication date

  1993-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/s0161-6420(93)31482-xPMID 8371917
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ocular effects of two different prostaglandin F2 alpha esters. A doublemasked cross-over study on normotensive eyes.

  2009cited by this paper
• Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes.

  1993cited by this paper
• Phenyl-substituted prostaglandins: potent and selective antiglaucoma agents.

  1993cited by this paper
• Intraocular pressure-reducing effect of PhXA41 in ocular hypertension. Comparison of dose regimens.

  1993cited by this paper
• Effects of PhXA41, A New Prostaglandin F2α Analog, on Aqueous Humor Dynamics in Human Eyes

  1993cited by this paper
• Intraocular pressure reduction with PhXA34, a new prostaglandin analogue, in patients with ocular hypertension.

  1992cited by this paper
• Pharmacology of Glaucoma

  1992cited by this paper
• PhXA34--a prostaglandin F2 alpha analogue. Effect on intraocular pressure in patients with ocular hypertension.

  1992cited by this paper
• Phenyl substituted prostaglandin analogs for glaucoma treatment

  1992cited by this paper
• PhXA34, a new potent ocular hypotensive drug. A study on dose-response relationship and on aqueous humor dynamics in healthy volunteers.

  1991cited by this paper
• Additivity of Prostaglandin F2α-1-Isopropyl Ester to Timolol in Glaucoma Patients

  1991cited by this paper
• Additivity of prostaglandin F2 alpha-1-isopropyl ester to timolol in glaucoma patients.

  1991cited by this paper
• The effect of adding prostaglandin F2 alpha-isopropylester to timolol in patients with open angle glaucoma.

  1990cited by this paper
• Maintained reduction of intraocular pressure by prostaglandin F2 alpha-1-isopropyl ester applied in multiple doses in ocular hypertensive and glaucoma patients.

  1989cited by this paper
• The ocular hypotensive effects and side effects of prostaglandins on the eyes of experimental animals.

  1989cited by this paper
• The ocular effects of prostaglandins and other eicosanoids.

  1989cited by this paper
• Prostaglandin F2 alpha-isopropylester eye drops: effect on intraocular pressure in open-angle glaucoma.

  1989cited by this paper
• Prostaglandin F2 alpha-isopropylester eye drops: effects in normal human eyes.

  1989cited by this paper
• Prostaglandin F2 alpha-1-isopropylester lowers intraocular pressure without decreasing aqueous humor flow.

  1988cited by this paper
• The effect of prostaglandin F2 alpha on intraocular pressure in normotensive human subjects.

  1988cited by this paper
• The effects of prostaglandin F2 alpha in the human eye.

  1985cited by this paper
• Shortterm "escape" and longterm "drift." The dissipation effects of the beta adrenergic blocking agents.

  1983cited by this paper
• [The effect of timolol eye drops on the intraocular pressure in simple glaucoma (author's transl)].

  1978cited by this paper

• Promise of latanoprost and timolol loaded combinatorial nanosheet for therapeutic applications in glaucoma

  2020cites this paper
• Episcleral Venous Pressure and the Ocular Hypotensive Effects of Topical and Intracameral Prostaglandin Analogs

  2019cites this paper
• Dose–Response of Intracameral Bimatoprost Sustained-Release Implant and Topical Bimatoprost in Lowering Intraocular Pressure

  2019cites this paper
• Topical treatment of glaucoma: established and emerging pharmacology

  2017cites this paper
• Prostaglandin analogues: past, present, and future

  2017cites this paper
• Latanoprost-Eluting Contact Lenses in Glaucomatous Monkeys.

  2016cites this paper
• The Placebo Effect in Early-Phase Glaucoma Clinical Trials

  2015cites this paper
• Effects of antiglaucoma drugs on blood flow of optic nerve heads and related structures

  2013cites this paper
• Intraocular pressure efficacy of glaucoma medications versus placebo in phase II compared to later phase trials

  2012cites this paper
• A 4-week, dose-ranging study comparing the efficacy, safety and tolerability of latanoprost 75, 100 and 125 μg/mL to latanoprost 50 μg/mL (xalatan) in the treatment of primary open-angle glaucoma and ocular hypertension

  2012influential citation
• A Correlation Between Latanoprost-induced Conjunctival Hyperemia and Intraocular Pressure-lowering Effect

  2011cites this paper
• The Use of Prostaglandin Analogs in the Uveitic Patient

  2011cites this paper
• Development and validation of a liquid chromatography/electrospray ionization tandem mass spectrometry method for the quantification of latanoprost free acid in rabbit aqueous humor and ciliary body.

  2011cites this paper
• Prostaglandin Efficacy and Safety Study Undertaken by Race (The PRESSURE Study)

  2010cites this paper
• Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension

  2010cites this paper
• CHAPTER 23 – Prostaglandins

  2009cites this paper
• The short-time effect of latanoprost on the intraocular pressure in normal pressure glaucoma.

  2009cites this paper
• A 6-month, randomized, double-masked comparison of latanoprost with timolol in patients with open angle glaucoma or ocular hypertension.

  2009cites this paper
• A panel assessment of glaucoma management: modification of existing RAND-like methodology for consensus in ophthalmology. Part I: Methodology and design.

  2008cites this paper
• First-line therapy with latanoprost 0.005% results in improved ocular circulation in newly diagnosed primary open-angle glaucoma patients: a prospective, 6-month, open-label study

  2008cites this paper
• Predictive value of the efficacy of glaucoma medications in regulatory trials: Phase I–III to post-marketing studies

  2008cites this paper
• Discrepancy of the Intraocular Pressure Response Between Fellow Eyes in One-eye Trials Versus Bilateral Treatment: Verification With Normal Subjects

  2008cites this paper
• Case Study: Latanoprost: Isopropylester of a Prostaglandin F2α Analog

  2007cites this paper
• Comparative efficacy of pilocarpine, timolol and latanoprost in experimental models of glaucoma.

  2007cites this paper
• Efficacy and safety of latanoprost versus travoprost in exfoliative glaucoma patients.

  2007cites this paper
• Short-term effects of latanoprost on anterior chamber depth in patients with glaucoma or ocular hypertension.

  2006cites this paper
• Concentration of latanoprost ophthalmic solution after 4 to 6 weeks' use in an eye clinic setting.

  2006cites this paper
• Circadian Intraocular Pressure Control with Dorzolamide versus Timolol Maleate Add-On Treatments in Primary Open-Angle Glaucoma Patients Using Latanoprost

  2006cites this paper
• Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma

  2005cites this paper
• Comparison of Latanoprost Monotherapy and Combined Therapy of 0.5% Timolol and 1% Dorzolamide in Chronic Primary Angle-Closure Glaucoma (CACG) in Japanese Patients

  2005cites this paper
• Degree of angle closure and the intraocular pressure-lowering effect of latanoprost in subjects with chronic angle-closure glaucoma.

  2005cites this paper
• The effect of latanoprost 0.005% once daily versus 0.0015% twice daily on intraocular pressure and aqueous humour protein concentration in glaucoma patients. A randomized, double-masked comparison with timolol 0.5%

  2005cites this paper
• Evolving Paradigms in the Medical Treatment of Glaucoma

  2004cites this paper
• Additive effect of latanoprost and dorzolamide in patients with elevated intraocular pressure

  2004cites this paper
• Intraocular pressure-reducing effects and safety of latanoprost versus timolol in patients with chronic angle-closure glaucoma.

  2004cites this paper
• Studies on ocular inflammation and development of a prostaglandin analogue for glaucoma treatment.

  2004cites this paper
• Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost.

  2003cites this paper
• Effects of Prostaglandin F2α and Latanoprost on Phosphoinositide Turnover, Myosin Light Chain Phosphorylation and Contraction in Cat Iris Sphincter

  2003cites this paper
• Conjunctival Hyperemia and the Use of Topical Prostaglandins in Glaucoma and Ocular Hypertension

  2003cites this paper
• Agents Acting on Prostanoid Receptors

  2003cites this paper
• Latanoprost for the prevention of ocular hypertension after neodymium:yttrium-aluminumgarnet laser posterior capsulotomy

  2002cites this paper
• Paradoxical intraocular pressure elevation after combined therapy with latanoprost and bimatoprost.

  2002cites this paper
• Trends in glaucoma surgery incidence and reimbursement for physician services in the Medicare population from 1995 to 1998.

  2002cites this paper
• HLA-DR Expression in Conjunctival Cells After Latanoprost

  2002cites this paper
• A Retrospective Review of Non-Responders to Latanoprost

  2002cites this paper
• Optimization of RNA isolation from human ocular tissues and analysis of prostanoid receptor mRNA expression using RT-PCR.

  2002cites this paper
• A functional study on prostanoid receptors involved in cultured human iridal melanocyte stimulation.

  2001cites this paper
• Effects of topical latanoprost on optic nerve head circulation in rabbits, monkeys, and humans.

  2001cites this paper
• Therapeutic potential of prostaglandin analogues in glaucoma

  2001cites this paper
• Latanoprost versus combined therapy with timolol plus dorzolamide: IOP-lowering effect in open-angle glaucoma.

  2001cites this paper
• From PGF(2alpha)-isopropyl ester to latanoprost: a review of the development of xalatan: the Proctor Lecture.

  2001cites this paper
• Einfluss von Latanoprost auf okuläre Hämodynamik und Kontrastsensitivität

  2001cites this paper
• [Effect of latanoprost on ocular hemodynamics and contrast sensitivity].

  2001cites this paper
• Topical Latanoprost and Optic Nerve Head and Retinal Circulation in Humans

  2001cites this paper
• Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension

  2001cites this paper
• The effect on intraocular pressure of latanoprost once or four times daily

  2001cites this paper
• Pharmacological Therapy for Glaucoma

  2000cites this paper
• Latanoprost: experience of 2-year treatment in Scandinavia.

  2000cites this paper
• Effect of Latanoprost on Intraocular Pressure in Steroid‐induced Glaucoma

  2000cites this paper
• Effect of topical latanoprost-timolol combined therapy on retinal blood flow and circulation of optic nerve head tissue in cynomolgus monkeys.

  2000cites this paper
• Pharmacological therapy for glaucoma: a review.

  2000cites this paper
• Design and development of controlled release veterinary drug delivery systems to the eye

  2000cites this paper
• A Preliminary Risk-Benefit Assessment of Latanoprost and Unoprostone in Open-Angle Glaucoma and Ocular Hypertension

  1999cites this paper
• Prostaglandin Analogues in the Treatment of Glaucoma

  1999cites this paper
• Effect of latanoprost on regional blood flow and capillary permeability in the monkey eye.

  1999cites this paper
• Aspects on prostanoid and cholinergic effects on aqueous humour dynamics in human eyes

  1999cites this paper
• Latanoprost in the treatment of glaucoma and ocular hypertension.

  1999cites this paper
• Interaction of pilocarpine with latanoprost in patients with glaucoma and ocular hypertension.

  1999cites this paper
• Perspectives in the medical treatment of glaucoma.

  1999cites this paper
• Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: a randomized, observer-masked multicenter study in patients with open-angle glaucoma. Italian Latanoprost Study Group.

  1999cites this paper
• Latanoprost. Two years' experience of its use in the United Kingdom. Latanoprost Study Group.

  1998cites this paper
• The pharmacokinetics of a new antiglaucoma drug, latanoprost, in the rabbit.

  1998cites this paper
• Molecular mechanisms of prostaglandin transport.

  1998cites this paper
• Prostaglandin derivates as ocular hypotensive agents.

  1998cites this paper
• Update in glaucoma: the new pharmacotherapies. Latanoprost.

  1998cites this paper
• Effects of Prostaglandin E2, F2α, and Latanoprost Acid on Isolated Ocular Blood Vessels In Vitro

  1998cites this paper
• [Latanoprost--a new prostaglandin F2 alpha analog in therapy of glaucoma--an overview].

  1998cites this paper
• Effects of latanoprost and dipivefrin, alone or combined, on intraocular pressure and on blood-aqueous barrier permeability

  1998cites this paper
• Latanoprost twice daily is less effective than once daily: indication of receptor subsensitivity?

  1998cites this paper
• Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections.

  1998cites this paper
• Management of Primary Open-Angle Glaucoma and Ocular Hypertension: The Potential Role of Latanoprost

  1998cites this paper
• in a patient with

  1998cites this paper
• Combined effect of dorzolamide and latanoprost on the rate of aqueous humor flow.

  1998cites this paper
• Initial clinical studies with prostaglandins and their analogues.

  1997cites this paper
• Prostaglandins alter extracellular matrix adjacent to human ciliary muscle cells in vitro.

  1997cites this paper
• Clinical dose-regimen studies with latanoprost, a new ocular hypotensive PGF2 alpha analogue.

  1997cites this paper
• Mediation of prostaglandin f2 alpha-induced ocular surface hyperemia by sensory nerves in rabbits.

  1997cites this paper
• A patient with long standing melanin laden macrophages in cerebrospinal fluid in Vogt–Koyanagi–Harada syndrome

  1997cites this paper
• Topical prostaglandins for glaucoma therapy.

  1997cites this paper
• New approaches to antiglaucoma therapy.

  1997cites this paper
• Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States.

  1997cites this paper
• Monitoring and evaluating cataract intervention in India

  1997cites this paper
• A previously unrecognised side effect of dapsone

  1997cites this paper
• Effects on IOP restoration and blood-aqueous barrier after long term treatment with latanoprost in open angle glaucoma and ocular hypertension

  1997cites this paper
• Ocular drug delivery in veterinary medicine.

  1997cites this paper
• [Glaucoma therapy with prostaglandin F2 alpha derivatives].

  1997cites this paper
• Effect of latanoprost on intraocular pressure in patients with glaucoma on maximal tolerated medical treatment

  1997cites this paper
• The molecular biology and ocular distribution of prostanoid receptors.

  1997cites this paper
• Glaukomtherapie mit Prostaglandin-F2α-Derivaten

  1997cites this paper
• A double masked comparison of the intraocular pressure reducing effect of latanoprost 0.005% and 0.001% administered once daily in open angle glaucoma and ocular hypertension

  1997cites this paper